Here, we observed that the activated kinase activity of MAPK7 might lead to the recruitment of CD8+ T cells to the tumor microenvironment and might contribute to favorable outcomes in patients receiving anti-PD-1 therapy. This evidence concerns the gene PDCD1 and neoplasm.